LifeCycle sells North American royalties for Fenoglide

08/21/2008 | Reuters

LifeCycle Pharma, a Danish biotech company, has sold the North American royalty stream from its drug Fenoglide to Cowen Healthcare Royalty Partners in a deal worth as much as $105 million. Fenoglide, a cholesterol-lowering treatment, entered the U.S. market this year through Sciele Pharma.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX